<DOC>
	<DOCNO>NCT01695616</DOCNO>
	<brief_summary>The purpose study evaluate effect Passiflora incarnata Isoflavone combination relieve symptom associate Climacteric Syndrome .</brief_summary>
	<brief_title>Efficacy Safety Passiflora Incarnata Isoflavona Combination Treatment Climacteric Symptoms</brief_title>
	<detailed_description>It know Hormone Therapy recommend postmenopausal woman reduce menopausal symptom prevent osteoporosis frame cardiovascular disease . However , 30 40 % woman still use hormone therapy . One reason woman continue reluctant start Hormone Therapy realize prescription hormone natural situation . Therefore , increase interest use prescription estrogen derive plant , know fitoestrogênios . The development drug contain two standardized extract focus two main symptom menopause : hot flash anxiety . This product come longing doctor respond promptly patient reach menopause already framework mild moderate anxiety . Thus , meet woman develop menopausal symptoms two highly prevalent menopause , cause intense discomfort routine woman , produce association Soy Passiflora aim control anxiety hot flush</detailed_description>
	<criteria>Female amenorrheic least one ( 1 ) year surgical menopause since dosage FSH ≥ 30 mIU / ml ; Age great equal 40 less equal 65 year ; Cytological examination colpo hold screen visit , Pap cytology classification class I II ; By mammography BIRADS classification ( fourth edition ) rat one ( 1 ) two ( 2 ) perform least six ( 6 ) month time inclusion screen visit research subject present recent survey ; Line endometrial ≤ 8 mm transvaginal ultrasound , perform screen visit , case subject intact uterus ; History severe liver renal disease discretion investigator ; Hypertension stage III uncontrolled ( SBP ≥ 180 mmHg DBP ≥ 110 mmHg ) ; Important cardiovascular disease coronary insufficiency dilate cardiomyopathy advance ; Using estrogen , progestin , steroid hormone replacement therapy ( HRT ) last 3 month ; Estrogendependent neoplasia ; Thromboembolic disorder less one year screen visit ; Anabolic drug use illicit drug use ; Hemoglobin &lt; 10 &gt; 17 g / dL ; TSH &lt; 0 , 550 &gt; 4 , 780 UUI / L ; FT4 &lt; 0.75 ηg / dL &gt; 1.8 ηg / dL ; Patient chronically use MAO inhibitor ( MAOIs ) levothyroxine</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>